UK-based biotechnology company, Iksuda Therapeutics, has completed a US$47m (£34m) financing round, which was led by Mirae Asset financial group and included a strategic investment from Korean biopharma player, Celltrion.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,